(Q31109981)

28 June 2017

title

Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data (English)

1 reference

28 June 2017

0 references

1 reference

1 reference

1 reference

1 reference

Mika Mäkelä

13

0 references

Jan Bonhoeffer

5

object named as

Jan Bonhoeffer

1 reference

28 June 2017

8

Ulrich Heininger

1 reference

28 June 2017

2

Michael S Gold

1 reference

28 June 2017

Glacus de Souza-Brito

7

object named as

Glacus de Souza Brito

1 reference

28 June 2017

10

Ali Khamesipour

1 reference

28 June 2017

Jens U Rüggeberg

1

1 reference

28 June 2017

José-Maria Bayas

3

1 reference

28 June 2017

Michael D Blum

4

1 reference

28 June 2017

Sheila Friedlander

6

1 reference

28 June 2017

Babatunde Imoukhuede

9

1 reference

28 June 2017

Michel Erlewyn-Lajeunesse

11

1 reference

28 June 2017

Susana Martin

12

1 reference

28 June 2017

Patricia Nell

14

1 reference

28 June 2017

Vitali Pool

15

1 reference

28 June 2017

Nick Simpson

16

1 reference

28 June 2017

Brighton Collaboration Anaphylaxis Working Group

17

1 reference

28 June 2017

language of work or name

English

0 references

publication date

12 March 2007

1 reference

28 June 2017

number of pages

10

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

28 June 2017

volume

25

1 reference

28 June 2017

issue

31

1 reference

28 June 2017

page(s)

5675-5684

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.064

28 June 2017

1 reference

Vaccine allergy: diagnosis and management

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.064

A revised nomenclature for allergy. An EAACI position statement from the EAACI nomenclature task force

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.064

Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.064

Symposium on the definition and management of anaphylaxis: summary report.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.064

Prevalence of anti-gelatin IgE antibodies in people with anaphylaxis after measles-mumps rubella vaccine in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.064

Serious adverse events after measles-mumps-rubella vaccination during a fourteen-year prospective follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.064

Risk of Anaphylaxis After Vaccination of Children and Adolescents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.064

Anaphylaxis from yellow fever vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.064

Safe administration of the measles vaccine to children allergic to eggs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.064

Second symposium on the definition and management of anaphylaxis: summary report--Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.064

The development of standardized case definitions and guidelines for adverse events following immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.064

Allergic reactions to measles-mumps-rubella vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.064

Anaphylaxis in children: clinical and allergologic features

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.064

Biphasic systemic anaphylaxis: an inpatient and outpatient study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.064

Biphasic and protracted anaphylaxis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.064

Biphasic anaphylactic reactions in pediatrics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.064

Postmortem findings after fatal anaphylactic reactions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.064

Mast cell tryptase: a review of its physiology and clinical significance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.064

Time course of appearance and disappearance of human mast cell tryptase in the circulation after anaphylaxis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.064

Ophthalmological and Biological Features of the Oculorespiratory Syndrome after Influenza Vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.064

Oculo-respiratory syndrome: a new influenza vaccine-associated adverse event?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.064

The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.064

Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.064

Meta-analysis of Observational Studies in Epidemiology: A Proposal for Reporting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.064

10.1016/J.VACCINE.2007.02.064

7 January 2021

Identifiers

DOI

1 reference

28 June 2017

1 reference